🧪Charlie Emerging therapies and research areas in CIDP
Eduardo Nobile-Orazio discusses how newer therapies for CIDP work, highlights current unmet treatment needs, and outlines how emerging studies are beginning to address these gaps. View transcript.
Watch next 📚
Transcript: Emerging therapies and research areas in CIDP
Read a transcript of Eduardo Nobile-Orazio discussing new CIDP therapies, unmet needs, and how emerging research is starting to address treatment gaps.
Transcript: Non-pharmaceutical disease management for CIDP
Read a transcript of Eduardo Nobile-Orazio discussing non-pharmaceutical disease management approaches for patients with CIDP.
Transcript: Determining appropriate initial treatment in CIDP
Read a transcript of Eduardo Nobile-Orazio discussing his approach to selecting the most appropriate initial CIDP treatment for patients.
🔊 “Quick Soundbite: What’s the future of this therapy?”
🧠Key Takeaways from the Expert Insight
-
CIDP is a chronic autoimmune disorder affecting peripheral nerves, often misdiagnosed due to its subtle progression.
-
Emerging therapies focus on immune modulation and nerve repair, aiming to improve long-term outcomes and reduce relapse rates.
-
Dr. Eduardo Nobile-Orazio highlights the evolving role of biologics and precision medicine in tailoring treatment to individual patient profiles.
-
Early diagnosis and intervention remain critical, with nerve conduction studies playing a central role in confirmation.
-
Future research is exploring biomarkers and novel immunotherapies to better predict response and personalize care.
📝Eduardo Nobile-Orazio, MD, PhD
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speakers and is not adjusted by Medthority.
Immunoglobulin and Steroid Use
The only therapy who basically affect the immune system, and immunoglobulin, they take under control the therapy, but they do not, you have to take this therapy until the patient go in remission. But they will need again to take the therapy. Steroids we cannot use for a long period of time, but they're effective on the immune system.
Mechanisms of Current Treatments
The sign is that they're sort of immunosuppressive, they block the immune system. Plasma change just remove the antibodies and all the new therapies that are made are not curing the disease. They are blocking possibly the mechanism of complement. They facilitating the internal catabolic destruction of the immunoglobulin. But this does not prevent that the immune system is still active, still produce antibodies, they produce complement. So the patient is not cured. All this effective therapy, we're just treating the patient.
The Role of Immunosuppressive Therapy
The patient is treated because, you know, we block the mechanism of the patient. So I think ideally, I think we should have an immunosuppressive therapy. We did a study with rituximab, unfortunately the results were not that exciting, but at least to have a disease, a therapy, they block the immuno pathogenetic mechanism at the basis, not, you know, the terminal step of this immunopathogenesis, but block the immune system, like it's most autoimmune disease. You know, just want to block the autoimmunity that cause the disease.
Future Research and Early Intervention
So that is most important and that need to find an immunosuppressive therapy who block the immune system. So the patient with this therapy, they know that the disease is blocked. I know that there is another study that they're doing, they're trying to do in United States with the same molecule, which is another immunosuppressive. And I am most, you know, now most, we are doing another studies in early onset CIDP just to see whether this therapy might be effective early in disease. Because it might be also important because we saw another disease like myasthenia gravis that if you treat the patient very early in the disease, you can stop the disease with rituximab. But if you do later on, you know, the immune system become sort of, you know, is more resistant to this therapy. So that is another part. I think that is where we should go.
of interest
are looking at
saved
next event
💬 Share Your Thoughts
What’s your experience with CIDP therapies? Seen similar cases in your practice?
Join the Conversation